WO2003089000A3 - Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4 - Google Patents

Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4 Download PDF

Info

Publication number
WO2003089000A3
WO2003089000A3 PCT/FR2003/001234 FR0301234W WO03089000A3 WO 2003089000 A3 WO2003089000 A3 WO 2003089000A3 FR 0301234 W FR0301234 W FR 0301234W WO 03089000 A3 WO03089000 A3 WO 03089000A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
production method
polyanion
composition
hiv composition
Prior art date
Application number
PCT/FR2003/001234
Other languages
English (en)
Other versions
WO2003089000A2 (fr
Inventor
Romain Vives
Claudio Vita
Hugues Lortat-Jacob
Original Assignee
Commissariat Energie Atomique
Centre Nat Rech Scient
Romain Vives
Sattentau
Claudio Vita
Hugues Lortat-Jacob
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique, Centre Nat Rech Scient, Romain Vives, Sattentau, Claudio Vita, Hugues Lortat-Jacob filed Critical Commissariat Energie Atomique
Priority to CA2481325A priority Critical patent/CA2481325C/fr
Priority to EP03746844A priority patent/EP1496932A2/fr
Priority to US10/509,686 priority patent/US7494975B2/en
Priority to JP2003585751A priority patent/JP5004408B2/ja
Priority to AU2003246840A priority patent/AU2003246840A1/en
Publication of WO2003089000A2 publication Critical patent/WO2003089000A2/fr
Publication of WO2003089000A3 publication Critical patent/WO2003089000A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte à une composition anti-VIH et à son procédé de fabrication. La composition de la présente invention comprend un polyanion et une molécule capable d'induire l'exposition de l'épitope CD4i de la protéine virale gp120. Le polyanion peut être choisi par exemple dans le groupe constitué de l'héparine, de l'héparane sulfate, et d'un polyanion équivalent à l'héparine ou à l'héparane sulfate. La molécule capable d'induire l'exposition de l'épitope CD4i de la protéine virale gp120 est un peptide CD4 ou un dérivé de celui-ci. La présente invention se rapporte également à l'utilisation de ladite composition pour la fabrication d'un médicament, notamment d'un médicament destiné au traitement du sida.
PCT/FR2003/001234 2002-04-19 2003-04-17 Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4 WO2003089000A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2481325A CA2481325C (fr) 2002-04-19 2003-04-17 Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
EP03746844A EP1496932A2 (fr) 2002-04-19 2003-04-17 Composition anti-vih, procede de fabrication et medicament.
US10/509,686 US7494975B2 (en) 2002-04-19 2003-04-17 Anti-HIV composition, production method thereof and medicament
JP2003585751A JP5004408B2 (ja) 2002-04-19 2003-04-17 抗ｈｉｖ組成物、その製造方法及び医薬
AU2003246840A AU2003246840A1 (en) 2002-04-19 2003-04-17 Anti-hiv composition, production method thereof and medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204926A FR2838649B1 (fr) 2002-04-19 2002-04-19 Composition anti-vih, procede de fabrication et medicament
FR02/04926 2002-04-19

Publications (2)

Publication Number Publication Date
WO2003089000A2 WO2003089000A2 (fr) 2003-10-30
WO2003089000A3 true WO2003089000A3 (fr) 2004-04-08

Family

ID=28686195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001234 WO2003089000A2 (fr) 2002-04-19 2003-04-17 Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4

Country Status (7)

Country Link
US (1) US7494975B2 (fr)
EP (1) EP1496932A2 (fr)
JP (1) JP5004408B2 (fr)
AU (1) AU2003246840A1 (fr)
CA (1) CA2481325C (fr)
FR (1) FR2838649B1 (fr)
WO (1) WO2003089000A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144685A1 (fr) * 2006-06-13 2007-12-21 Commissariat A L'energie Atomique Peptides mimétiques du cd4 et utilisations de ceux-ci
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2087911A1 (fr) 2008-02-06 2009-08-12 Institut Pasteur Molécules conjuguées comprenant un peptide dérivé du récepteur CD4 couplé à un polyanion pour le traitement du SIDA
CN108640977A (zh) * 2018-06-18 2018-10-12 上海大学 特异性结合HIV上包膜糖蛋白gp120的多肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249390A2 (fr) * 1986-06-03 1987-12-16 Candace B. Pert Peptides synthétiques, relatifs à l'HIV-glycoprotéine gp 120
EP0332952A2 (fr) * 1988-03-12 1989-09-20 BASF Aktiengesellschaft Combinaisons d'héparines polysulfatées pour combattre les infections rétrovirales
WO1992004909A1 (fr) * 1990-09-25 1992-04-02 M.L. Laboratories Plc Composition pharmaceutique contenant la glycoproteine cd4 et un agent polyanionique anti-vih et son utilisation
WO2002059146A2 (fr) * 2001-01-23 2002-08-01 Commissariat A L'energie Atomique Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61565B1 (en) * 1988-08-24 1994-11-16 Akzo Nv Heparin fragments and fractions with anti-HIV action
JPH0959178A (ja) * 1995-08-24 1997-03-04 Samu Kenkyusho:Kk 抗ウイルス剤及び抗ウイルス作用増強剤
JPH1029952A (ja) * 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249390A2 (fr) * 1986-06-03 1987-12-16 Candace B. Pert Peptides synthétiques, relatifs à l'HIV-glycoprotéine gp 120
EP0332952A2 (fr) * 1988-03-12 1989-09-20 BASF Aktiengesellschaft Combinaisons d'héparines polysulfatées pour combattre les infections rétrovirales
WO1992004909A1 (fr) * 1990-09-25 1992-04-02 M.L. Laboratories Plc Composition pharmaceutique contenant la glycoproteine cd4 et un agent polyanionique anti-vih et son utilisation
WO2002059146A2 (fr) * 2001-01-23 2002-08-01 Commissariat A L'energie Atomique Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARROP HILARY A ET AL: "Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.", AIDS (PHILADELPHIA), vol. 8, no. 2, 1994, pages 183 - 192, XP002226783, ISSN: 0269-9370 *
MOULARD MAXIME ET AL: "Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.", JOURNAL OF VIROLOGY, vol. 74, no. 4, February 2000 (2000-02-01), pages 1948 - 1960, XP002226781, ISSN: 0022-538X *
SULLIVAN NANCY ET AL: "Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.", JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08-01), pages 6332 - 6338, XP002226782, ISSN: 0022-538X *
WITVROUW M ET AL: "SULFATED POLYSACCARIDES EXTRACTED FROM SEA ALGAE AS POTENTIAL ANTIVIRAL DRUGS", GENERAL PHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 29, no. 4, 1997, pages 497 - 511, XP002056013, ISSN: 0306-3623 *

Also Published As

Publication number Publication date
JP5004408B2 (ja) 2012-08-22
AU2003246840A8 (en) 2003-11-03
FR2838649A1 (fr) 2003-10-24
FR2838649B1 (fr) 2006-01-13
CA2481325A1 (fr) 2003-10-30
CA2481325C (fr) 2011-07-26
JP2005528405A (ja) 2005-09-22
US20060084593A1 (en) 2006-04-20
US7494975B2 (en) 2009-02-24
EP1496932A2 (fr) 2005-01-19
WO2003089000A2 (fr) 2003-10-30
AU2003246840A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
WO2004071426A3 (fr) Composes destines au traitement d'une infection virale
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2006077601A3 (fr) Peptides de fusion vih-1 gp41 pour une immunomodulation
HUP0001379A2 (hu) Készítmény humán immundeficiencia vírus és más vírusfertőzések okozta betegségek antimikrobás megelőzésére és kezelésére
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
WO2005063764A3 (fr) Nouveaux pyrrolocarbazoles fusionnes
AU2002353775A1 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
WO2003051926A3 (fr) Proteine de fusion anti-cd7
WO1997005899A3 (fr) Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration
MY126450A (en) Crystalline efavirenz
WO2003089000A3 (fr) Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2003082895A3 (fr) Procede de preparation de l'eplerenone
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények
WO2006030323A3 (fr) Composes inhibant le replication du virus de l'immunodeficience humaine
WO2022109317A9 (fr) Anticorps contre la grippe et combinaisons de ces derniers
WO2002056902A3 (fr) Procede de combinaison permettant de traiter des infections virales
WO1996001110A3 (fr) Triple combinaison anti-vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003746844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2481325

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006084593

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10509686

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003585751

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003746844

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10509686

Country of ref document: US